Clinuvel Pharmaceuticals Limited CLVLY
6.74 USD 0.00 (+0.00%)
Aug 10, 2026, 9:30 AM EDT
6.74 Day range 6.74
5.98 52-week range 9.00
- YTD
- -20.52%
- 1 year
- -3.44%
News
globenewswire.com A decade of profitability provides foundation for CLINUVEL's U.S. expansion CLINUVEL PHARMACEUTICALS LTD announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026).
globenewswire.com CLINUVEL implements strategic reorganisation to refocus on U.S. markets MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce,…
globenewswire.com CLINUVEL's ADS to commence trading on Nasdaq MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the…
globenewswire.com SCENESSE® approved for EPP in Canada Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder
globenewswire.com CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease…
globenewswire.com CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL's innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual…
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2026 Earnings Call Transcript
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Shareholder/Analyst Call Transcript Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Shareholder/Analyst Call October 16, 2025 7:00 PM EDT Company Participants Jeffrey Rosenfeld Susan Smith Matthew Pringle Malcolm Bull - Head of…
globenewswire.com CLINUVEL to advance novel pharmaceutical formulations in preclinical program Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q4 2025 Earnings Conference Call August 28, 2025 4:00 AM ET Company Participants Malcolm Bull - Head of Australian Operations & Investor Relations Peter…
globenewswire.com CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL's primary listing on the ASX will…
globenewswire.com CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled
globenewswire.com Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025 MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11,…
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript Clinuvel Pharmaceuticals Limited (OTCPK:CLVLY) Q2 2025 Results Conference Call February 27, 2025 2:00 AM ET Company Participants Stella Mariss - Monsoon Communications Malcolm Bull - Head of IR Peter…
globenewswire.com CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE®…
globenewswire.com Afamelanotide in fair-skinned Parkinson's patients MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or…
globenewswire.com Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE®…
globenewswire.com Malibu shines a light on CLINUVEL's pioneering work in photomedicine MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California's most prolific investors and philanthropists at…
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript
seekingalpha.com Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2022 Results - Earnings Call Transcript
benzinga.com Stocks That Hit 52-Week Highs On Tuesday 
benzinga.com Stocks That Hit 52-Week Lows On Friday 
benzinga.com Stocks That Hit 52-Week Lows On Thursday 
benzinga.com Stocks That Hit 52-Week Lows On Wednesday - benzinga.com Stocks That Hit 52-Week Highs On Wednesday